Cannabix Technologies 12/15/2023 Earnings Report

Cannabix Technologies EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cannabix Technologies Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cannabix Technologies Announcement Details

• Date: 12/15/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Cannabix Technologies (OTCMKTS:BLOZF) is a Canada-based developer of bio­sensor technologies focused on the rapid, non-invasive detection of cannabis impairment. The company’s flagship product is a handheld breathalyzer device designed to identify recent use of tetrahydrocannabinol (THC) within minutes of exhalation, offering law enforcement agencies, public safety organizations and workplace safety departments a potential tool to assess impairment in real time.

The Cannabix breathalyzer employs proprietary sensor arrays and on-board algorithms to distinguish THC molecules in breath samples, delivering results without the need for laboratory analysis. In addition to its cannabis detection platform, the company is exploring integration of alcohol and multi-drug screening capabilities to create a more comprehensive roadside and occupational testing solution. Cannabix has pursued partnerships with research institutions and regulatory bodies to validate its technology under controlled conditions.

Headquartered in Vancouver, British Columbia, Cannabix Technologies conducts its research and development activities at its Canadian laboratories and collaborates with external contract manufacturers for product assembly. The company’s management team is led by Chief Executive Officer Craig Ellins, who brings experience in technology commercialization and regulatory affairs. The board and executive suite also include professionals with backgrounds in biosensor engineering, public safety and diagnostics marketing.

As a publicly traded entity on the OTC Markets under the symbol BLOZF, Cannabix Technologies continues to advance its prototype toward regulatory approval and commercial rollout. Its primary markets include North America and select international jurisdictions considering roadside and workplace drug screening solutions, with ongoing efforts to secure government contracts and private-sector distribution agreements.